BACKGROUND: Chronic congestive heart failure is a common condition that, if untreated, markedly impairs the quality of life and is associated with a high risk of recurrent hospitalization and death. METHODS: This review is based on articles retrieved by a selective search in PubMed, as well as on relevant guidelines. RESULTS: Evidence-based treatment options are available only for congestive heart failure with a low ejection fraction. Pharma - cotherapy is based on neurohumoral inhibition of the renin-angiotensin-aldosterone system and the adrenergic system. The prognosis of patients with this condition has been further improved recently through the introduction of combined angiotensin receptor antagonists and neprilysin inhibitors. Modern implantable devices are a further component of treatment. Implantable defibrillators and special pacemakers for cardiac resynchronization are well established; the utility of alternative devices (baroreflex modulation or cardiac contractility modulation) needs to be investigated in further studies. It was recently shown that the catheter-based treatment of secondary mitral regurgitation with a MitraClip improves the outcome of selected patients. CONCLUSION: The treatment of chronic systolic heart failure as recommended in the relevant guidelines, with drugs and implanted devices if indicated, can significantly improve the clinical outcome.
BACKGROUND: Chronic congestive heart failure is a common condition that, if untreated, markedly impairs the quality of life and is associated with a high risk of recurrent hospitalization and death. METHODS: This review is based on articles retrieved by a selective search in PubMed, as well as on relevant guidelines. RESULTS: Evidence-based treatment options are available only for congestive heart failure with a low ejection fraction. Pharma - cotherapy is based on neurohumoral inhibition of the renin-angiotensin-aldosterone system and the adrenergic system. The prognosis of patients with this condition has been further improved recently through the introduction of combined angiotensin receptor antagonists and neprilysin inhibitors. Modern implantable devices are a further component of treatment. Implantable defibrillators and special pacemakers for cardiac resynchronization are well established; the utility of alternative devices (baroreflex modulation or cardiac contractility modulation) needs to be investigated in further studies. It was recently shown that the catheter-based treatment of secondary mitral regurgitation with a MitraClip improves the outcome of selected patients. CONCLUSION: The treatment of chronic systolic heart failure as recommended in the relevant guidelines, with drugs and implanted devices if indicated, can significantly improve the clinical outcome.
Authors: Anthony S L Tang; George A Wells; Mario Talajic; Malcolm O Arnold; Robert Sheldon; Stuart Connolly; Stefan H Hohnloser; Graham Nichol; David H Birnie; John L Sapp; Raymond Yee; Jeffrey S Healey; Jean L Rouleau Journal: N Engl J Med Date: 2010-11-14 Impact factor: 91.245
Authors: Faiez Zannad; John J V McMurray; Henry Krum; Dirk J van Veldhuisen; Karl Swedberg; Harry Shi; John Vincent; Stuart J Pocock; Bertram Pitt Journal: N Engl J Med Date: 2010-11-14 Impact factor: 91.245
Authors: Kirkwood F Adams; Javed Butler; J Herbert Patterson; Wendy Gattis Stough; Jerry L Bauman; Dirk J van Veldhuisen; Todd A Schwartz; Hani Sabbah; John I Mackowiak; Hector O Ventura; Jalal K Ghali Journal: Eur J Heart Fail Date: 2016-08 Impact factor: 15.534
Authors: Suzanne V Arnold; Khaja M Chinnakondepalli; John A Spertus; Elizabeth A Magnuson; Suzanne J Baron; Saibal Kar; D Scott Lim; Jacob M Mishell; William T Abraham; JoAnn A Lindenfeld; Michael J Mack; Gregg W Stone; David J Cohen Journal: J Am Coll Cardiol Date: 2019-03-17 Impact factor: 24.094
Authors: Marie Bayer Elming; Jens C Nielsen; Jens Haarbo; Lars Videbæk; Eva Korup; James Signorovitch; Line Lisbeth Olesen; Per Hildebrandt; Flemming H Steffensen; Niels E Bruun; Hans Eiskjær; Axel Brandes; Anna M Thøgersen; Finn Gustafsson; Kenneth Egstrup; Regitze Videbæk; Christian Hassager; Jesper Hastrup Svendsen; Dan E Høfsten; Christian Torp-Pedersen; Steen Pehrson; Lars Køber; Jens Jakob Thune Journal: Circulation Date: 2017-09-06 Impact factor: 29.690
Authors: Wojciech Zareba; Helmut Klein; Iwona Cygankiewicz; W Jackson Hall; Scott McNitt; Mary Brown; David Cannom; James P Daubert; Michael Eldar; Michael R Gold; Jeffrey J Goldberger; Ilan Goldenberg; Edgar Lichstein; Heinz Pitschner; Mayer Rashtian; Scott Solomon; Sami Viskin; Paul Wang; Arthur J Moss Journal: Circulation Date: 2011-02-28 Impact factor: 29.690
Authors: Kim Fox; Michel Komajda; Ian Ford; Michele Robertson; Michael Böhm; Jeffrey S Borer; Philippe Gabriel Steg; Luigi Tavazzi; Michal Tendera; Roberto Ferrari; Karl Swedberg Journal: Eur Heart J Date: 2013-03-26 Impact factor: 29.983
Authors: John J V McMurray; Henry Krum; William T Abraham; Kenneth Dickstein; Lars V Køber; Akshay S Desai; Scott D Solomon; Nicola Greenlaw; M Atif Ali; Yanntong Chiang; Qing Shao; Georgia Tarnesby; Barry M Massie Journal: N Engl J Med Date: 2016-04-04 Impact factor: 91.245
Authors: Piotr Ponikowski; Dirk J van Veldhuisen; Josep Comin-Colet; Georg Ertl; Michel Komajda; Viacheslav Mareev; Theresa McDonagh; Alexander Parkhomenko; Luigi Tavazzi; Victoria Levesque; Claudio Mori; Bernard Roubert; Gerasimos Filippatos; Frank Ruschitzka; Stefan D Anker Journal: Eur Heart J Date: 2014-08-31 Impact factor: 29.983
Authors: Marcus Dörr; Uwe Riemer; Michael Christ; Johann Bauersachs; Ralph Bosch; Ulrich Laufs; Anja Neumann; Martin Scherer; Stefan Störk; Rolf Wachter Journal: ESC Heart Fail Date: 2021-05-04
Authors: Jonas Neuser; Hans Julian Buck; Maximiliane Oldhafer; Jan-Thorben Sieweke; Udo Bavendiek; Johann Bauersachs; Julian D Widder; Dominik Berliner Journal: Front Cardiovasc Med Date: 2022-03-17
Authors: Christos Zormpas; Kai G Kahl; Stephan Hohmann; Hanno Oswald; Christopher Stiel; Christian Veltmann; Johann Bauersachs; David Duncker Journal: Front Psychiatry Date: 2022-06-17 Impact factor: 5.435